+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 74Years
All Genders
ID07217587

Comparing Nipocalimab and Efgartigimod Treatments for Adults with Generalized Myasthenia Gravis in a Randomized Open-Label Phase 3b Trial Including Switching from Efgartigimod to Nipocalimab

Led by Janssen Research & Development, LLC · Updated on 2026-11-03

115

Participants Needed

31

Research Sites

69 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how well nipocalimab works compared to efgartigimod in adults with generalized myasthenia gravis, a condition where the immune system attacks the connection between nerves and muscles causing weakness. This Phase 3b clinical trial aims to compare the effects of these two treatments on muscle strength and daily living activities in participants with confirmed antibody-positive generalized myasthenia gravis who have specific muscle weakness scores. Participants are assigned to one of three groups. One group receives nipocalimab intravenously with a loading dose on Day 1, then maintenance doses every two weeks until Week 12. Another group receives efgartigimod intravenously once a week for four weeks starting from Day 1, with the option to switch to nipocalimab between Week 4 and Week 12. The third group includes participants previously treated with efgartigimod they receive a nipocalimab loading dose on switch day, followed by maintenance doses every two weeks until switch Week 12. During the study, participants are regularly evaluated for changes in immunoglobulin G IgG levels, muscle strength, and daily living activities using standardized scores like the MG-ADL and QMG scales. Safety is closely monitored by tracking adverse events up to Week 20. Follow-up assessments occur at specified weeks to measure treatment effects and participant well-being. The total study duration extends up to 12 weeks of treatment or switch phase with ongoing safety evaluations.

CONDITIONS

Brief Title

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here